The clearance makes Jascayd the first new drug for idiopathic pulmonary fibrosis in over a decade, but some analysts see it as a “modest” advance in care.

Arthrosi Therapeutics has secured a nine-figure funding round to accelerate development of a new kind of gout medicine. The San Diego-based biotechnology startup on Wednesday revealed it has closed ...

A potentially $2 billion deal with InnoCare Pharma hands Zenas rights to a BTK inhibitor in late-stage testing for multiple sclerosis and two other immune medicines in earlier development.

Nilo Therapeutics, which launched Wednesday, is trying to develop drugs that regulate inflammation and the immune system by targeting a special kind of nerve cell.

The findings are the latest setback for weight loss medicines that target a specific cannabinoid receptor and are meant to boost the effects of incretin therapies like Wegovy.

Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that autoimmune diseases affect 400 to 600 million people worldwide, with the burden ...

The agency will consider a submission that includes pooled data from ongoing studies, a decision analysts viewed as a notable, additional sign of regulatory flexibility for gene therapies.

Implementing artificial intelligence requires significant human labor and technical expertise, threatening to create a digital divide between highly resourced health systems and safety-net providers.

Today, a brief rundown of news involving Gilead Sciences and Stoke Therapeutics, as well as updates from the Centers for Disease Control and Prevention, AstraZeneca and Trogenix that you may have ...

Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work at the big Indianapolis drugmaker.

The company set terms for an offering with the help of a little-used section of the Securities Act that would enable its IPO to price automatically in 20 days.

The results could pave the way for Datroway to supplant chemotherapy in certain triple-negative tumors, adding to existing clearances in other breast and lung malignancies.